scholarly journals Serum sclerostin levels in Paget's disease and prostate cancer with bone metastases with a wide range of bone turnover

Bone ◽  
2012 ◽  
Vol 51 (1) ◽  
pp. 153-157 ◽  
Author(s):  
Maria P. Yavropoulou ◽  
Antoon H. van Lierop ◽  
Neveen A.T. Hamdy ◽  
Rene Rizzoli ◽  
Socrates E. Papapoulos
Keyword(s):  
Prostate Cancer ◽  
Bone Turnover ◽  
Bone Metastases ◽  
Paget’S Disease ◽  
Paget's Disease ◽  
Wide Range

Paget’s disease of bone

2013 ◽  
pp. 1237-1244
Author(s):  
Stuart H. Ralston
Keyword(s):  
Bone Turnover ◽  
Viral Infections ◽  
Paget’S Disease ◽  
Paget's Disease ◽  
Paget’S Disease Of Bone ◽  
Bone Architecture ◽  
Paget's Disease Of Bone ◽  
Disease Extent ◽  
Rare Genetic Variants ◽  
Bone Scans

Paget’s disease of bone (PDB) affects up to 1% of people of European origin aged 55 years and above. It is characterized by focal increases in disorganized bone remodelling which disrupt normal bone architecture, causing the affected bones to enlarge and become weakened. This can lead to various complications including pain, deformity, fracture, nerve compression syndromes, and osteoarthritis. Genetic factors play a key role in the pathogenesis of PDB. This is mediated by a combination of rare genetic variants which cause familial forms of the disease and common variants which have additive effects on disease susceptibility. Suggested environmental factors for PDB include viral infections, calcium and vitamin D deficiency, and excessive mechanical loading of affected bones. The diagnosis can be made by the characteristic changes seen on radiographs, but isotope bone scans are a more sensitive method of defining disease extent. Serum total alkaline phosphatase levels are usually raised in patients with metabolically active disease and are often used as a measure of disease activity. Bisphosphonates are the treatment of choice for PDB; they reduce the elevations in bone turnover that are characteristic of the disease and are an effective treatment for bone pain. Among the bisphosphonates, zoledronic acid is most likely to give a favourable pain response. Bisphosphonate treatment should not be given with the primary aim of normalizing elevated biochemical markers of bone turnover since there is no evidence that this is beneficial. Although potent bisphosphonates can normalize elevated bone turnover in many patients with PDB, it unclear as yet whether this prevents complications of the disease.

Paget’s disease of bone

2013 ◽  
Author(s):  
Stuart H. Ralston
Keyword(s):  
Bone Turnover ◽  
Viral Infections ◽  
Serum Alkaline Phosphatase ◽  
Paget’S Disease ◽  
Paget's Disease ◽  
Bisphosphonate Therapy ◽  
Paget’S Disease Of Bone ◽  
Bone Architecture ◽  
Paget's Disease Of Bone ◽  
Disease Extent

Paget's disease of bone (PDB) affects up to 1% of people of European origin aged 55 years and above. It is characterized by focal abnormalities of bone remodelling which disrupt normal bone architecture, leading to expansion and reduced mechanical strength of affected bones. This can lead to various complications including deformity, fracture, nerve compression syndromes, and osteoarthritis, although many patients are asymptomatic. Genetic factors play a key role in the pathogenesis of PDB. This seems to be mediated by a combination of rare genetic variants which cause familial forms of the disease and common variants which increase susceptibility to environmental triggers. Environmental factors which have been suggested to predispose to PDB include viral infections, calcium and vitamin D deficiency, and excessive mechanical loading of affected bones. The diagnosis can be made by the characteristic changes seen on radiographs, but isotope bone scans are helpful in defining disease extent. Serum alkaline phosphatase levels can be used as a measure of disease activity. Inhibitors of bone resorption are the mainstay of medical management for PDB and bisphosphonates are regarded as the treatment of choice. Bisphosphonates are highly effective at reducing bone turnover in PDB and have been found to heal osteolytic lesions, and normalize bone histology. Although bisphosphonates can improving bone pain caused by elevated bone turnover, most patients require additional therapy to deal with symptoms associated with disease complications. It is currently unclear whether bisphosphonate therapy is effective at preventing complications of PDB.

THE EFFECT OF NASAL hCT ON BONE TURNOVER IN PAGET'S DISEASE OF BONE—IMPLICATIONS FOR THE TREATMENT OF OTHER METABOLIC BONE DISEASES

Rheumatology ◽  
1992 ◽  
Vol 31 (1) ◽  
pp. 35-39 ◽  
Author(s):  
J. Y. REGINSTER ◽  
A. M. JEUGMANS-HUYNEN ◽  
M. WOUTERS ◽  
N. SARLET ◽  
H. D. MCINTYRE ◽  
...  
Keyword(s):  
Bone Turnover ◽  
Paget’S Disease ◽  
Paget's Disease ◽  
Bone Diseases ◽  
Paget’S Disease Of Bone ◽  
Paget's Disease Of Bone ◽  
Metabolic Bone Diseases ◽  
Metabolic Bone

scholarly journals Markers of bone turnover for the management of patients with bone metastases from prostate cancer

2000 ◽  
Vol 82 (4) ◽  
pp. 858-864 ◽  
Author(s):  
P Garnero ◽  
N Buchs ◽  
J Zekri ◽  
R Rizzoli ◽  
R E Coleman ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Turnover ◽  
Bone Metastases ◽  
Markers Of Bone Turnover

Usefulness of biochemical markers of bone turnover in assessing response to the treatment of paget’s disease

Bone ◽  
2001 ◽  
Vol 29 (5) ◽  
pp. 447-452 ◽  
Author(s):  
L Alvarez ◽  
N Guañabens ◽  
P Peris ◽  
S Vidal ◽  
I Ros ◽  
...  
Keyword(s):  
Bone Turnover ◽  
Biochemical Markers ◽  
Paget’S Disease ◽  
Paget's Disease ◽  
Markers Of Bone Turnover
Sign in / Sign up

Export Citation Format

Share Document